Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib versus platinum-based standard of care in first-line RET fusion-positive metastatic non-small cell lung cancer
NL-OMON50248Phase 3Recruiting
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pralsetinib with Investigator's choice platinum-based standard of care (2 arms). Primary endpoint: Progression-free survival. Started Feb 2021; status: recruiting.
02
Drugs
pralsetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON50248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50248.